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SUMMARY
Background
Minimal hepatic encephalopathy (MHE) reduces quality of life, increases the
risk of road trafﬁc incidents and predicts progression to overt hepatic enceph-
alopathy and death. Current psychometry-based diagnostic methods are effec-
tive, but time-consuming and a universal ‘gold standard’ test has yet to be
agreed upon. Critical Flicker Frequency (CFF) is a proposed language-inde-
pendent diagnostic tool for MHE, but its accuracy has yet to be conﬁrmed.
Aim
To assess the diagnostic accuracy of CFF for MHE by performing a system-
atic review and meta-analysis of all studies, which report on the diagnostic
accuracy of this test.
Methods
A systematic literature search was performed to locate all publications
reporting on the diagnostic accuracy of CFF for MHE. Data were extracted
from 2 9 2 tables or calculated from reported accuracy data. Collated data
were meta-analysed for sensitivity, speciﬁcity, diagnostic odds ratio (DOR)
and summary receiver operator curve (sROC) analysis. Prespeciﬁed sub-
group analysis and meta-regression were also performed.
Results
Nine studies with data for 622 patients were included. Summary sensitivity
was 61% (95% CI: 55–67), speciﬁcity 79% (95% CI: 75–83) and DOR 10.9
(95% CI: 4.2–28.3). A symmetrical sROC gave an area under the receiver
operator curve of 0.84 (SE = 0.06). The heterogeneity of the DOR was 74%.
Conclusions
Critical Flicker Frequency has a high speciﬁcity and moderate sensitivity
for diagnosing minimal hepatic encephalopathy. Given the advantages of
language independence and being both simple to perform and interpret, we
suggest the use of critical ﬂicker frequency as an adjunct (but not replace-
ment) to psychometric testing.
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INTRODUCTION
Minimal hepatic encephalopathy (MHE) is an important
clinical variant of hepatic encephalopathy (HE), which
occurs in up to 60–70% of patients with cirrhosis.1, 2
The condition comprises a cognitive impairment,
observed in patients with cirrhosis who have no clinical
evidence of overt hepatic encephalopathy (OHE).3 It is
associated with an increased incidence of road trafﬁc
accidents,4–7 reduced quality of life and it affects the abil-
ity to perform tasks of daily living.8, 9 It has also been
shown to increase the risk of progressing to OHE and
inversely correlates with survival in some studies.10–12.
Treatment for MHE can improve psychometric per-
formance and health-related quality of life.13–17 It is
therefore clinically useful that MHE is diagnosed effec-
tively in patients with this condition. A quick, accurate,
objective, cost-effective and well-validated diagnostic test
is an unmet clinical need and would simplify the early
management algorithm for this condition.
Minimal hepatic encephalopathy is not routinely
tested, even in specialised cirrhosis clinics. A survey
among members of the American Association for the
Study of Liver Diseases (AASLD) showed that 72%
tested less than half their patients for MHE, despite 84%
acknowledging that MHE is a signiﬁcant problem. Fur-
thermore, 85% said that if clinical staff could perform a
quick, accurate test, this would increase the likelihood
that people would test for MHE.18
There are many diagnostic tests for MHE, but no uni-
versal ‘gold standard’ test. The Expert Working Group in
1998 suggested that the psychometric hepatic encepha-
lopathy score (PHES) should be considered the gold
standard test.19 PHES is a selection of ﬁve psychometric
test batteries that has been validated in Italian,20 Ger-
man21, 22 and Spanish23 cohorts. However, performing
this battery can be time consuming and prone to bias
from disturbance, mood and interaction with the tester.
Computer-assisted tests have also been used to diag-
nose MHE and include the Inhibitory Control Test
(ICT),24, 25 the cognitive drug research system (CDRS),26
the continuous reaction time test (CRT)27, 28 and Critical
Flicker Frequency (CFF).29 The CFF has the purported
advantages of not being dependent on language, verbal
ﬂuency, numeracy or numerics, and therefore studies
into its use have been performed in the United States,
Europe and Asia.
The CFF was devised originally as an ophthalmologi-
cal test used to measure visual acuity and to screen for
optic nerve lesions.30 This test measures the frequency at
which the patient perceives that a fused/single light
becomes a ﬂickering light. The device causes a stepwise
decrease in frequency from 60 to 25 Hz. This is done
multiple times (usually 8–10) to allow calculation of the
mean and standard deviation. It may also be performed
in reverse, where the patient determines the frequency at
which a ﬂickering light becomes continuous or ‘fused’.
This test has the advantage of being able to be carried
out by clinical personnel using a portable device with
limited running costs.31
The CFF has been in limited clinical and research use
for a decade, but its diagnostic accuracy has never been
subjected to quantitative review. We therefore performed
a systematic review and meta-analysis of CFF to fully
assess its diagnostic accuracy in detecting MHE and to
guide future implementation.
MATERIALS AND METHODS
Search methodology
We searched MEDLINE and EMBASE using OvidSP for
articles between January 1948 and November 2012,
which reported on the diagnostic accuracy of CFF for
MHE. The search terms used were ‘Critical Flicker Fre-
quency’ OR ‘CFF’ in conjunction (AND) with ‘Diagnos-
tic Accuracy’ OR MeSH term ‘Diagnostic techniques and
procedures’ OR ‘Sensitivity’ OR ‘Speciﬁcity’. Inclusion
criteria were adult studies reporting the diagnostic accu-
racy for CFF in patients with cirrhosis and/or portosys-
temic bypass. Paediatric studies, studies not related to
MHE in the context of cirrhosis or portosystemic bypass,
those which did not refer to a gold standard and those
not in the English language were excluded. We also
obtained primary sources from tracking references from
hand searches in review papers and original articles.
Only original data were used in the meta-analysis.
Data extraction
Test performance data were extracted as a 2 9 2 table of
true negative, true positive, false positive and false nega-
tive values directly from tabulated results. If these were
not available, they were calculated from reported sensi-
tivity, speciﬁcity, positive predictive value and/or negative
predictive values; if this were not possible, the authors
were contacted for more detailed data; and if this was
not possible or there was doubt over the 2 9 2 calcula-
tion, the study was excluded from subsequent analysis.
Assessment of study quality
Studies meeting the above criteria were quality assessed
using positive scoring in a modiﬁed 23-point Standards
528 Aliment Pharmacol Ther 2013; 37: 527-536
ª 2013 Blackwell Publishing Ltd
F. J. Torlot et al.
for the Reporting of Diagnostic Accuracy Studies
(STARD) pro forma.32, 33 We modiﬁed this scoring sys-
tem from 25 to 23 as two points were not relevant to this
study (points 18 and 20). Two readers (FT and MM)
independently assessed all included studies according to
the prearranged pro forma. An open discussion was then
held to determine any disagreement between the readers.
Studies were then segregated into ‘low’ or ‘high’ quality
depending on whether they met < or > than 50% of the
study quality pro forma (Low <12/23, High  12/23).
Data analysis
The DerSimonian-Laird random effects method was used
to produce summary estimates of sensitivity, speciﬁcity,
likelihood ratios (LR) and diagnostic odds ratio (DOR).
Conﬁdence intervals for sensitivity and speciﬁcity were
calculated using F-distribution method for the binomial
proportion.34 The summary receiver operator curve
(sROC) was used to graphically determine performance
following testing for correlation between sensitivity and
speciﬁcity [as logit true positive rate (TPR) vs. logit false
positive rate (FPR)] to explore for threshold effects and
subsequent assessment for constant DOR using the
Moses-Sharpiro-Littenburg model.35 Symmetrical or
asymmetrical sROC were used depending on whether
the DOR is constant. Heterogeneity was investigated
using pre-planned subgroup analysis and calculated by
the I2 method.36 Pre-planned subgroups were deﬁned
according to: study quality (low or high with 50% quality
pro forma cut-off used), type of gold standard test
(PHES or non-PHES), study location (Europe or non-
European), CFF cut-off ( 38 or  39), whether the
study was published in early era or late era (median
study year from extracted studies was used as the cut-
off), number of patients in the respective studies (<50
subjects or  50 subjects)(50 = median) and the aetiol-
ogy of the MHE (cirrhosis or bypass/shunts).
A funnel plot and effective sample size (ESS) regres-
sion analysis (the logarithm of the DOR plotted against
1/√ESS) was used to investigate publication bias. 1/√ESS
is proportional to root (1/n1 + 1/n2) where n1 = num-
ber diseased and n2 number not diseased.37 Data analy-
ses were performed using the freeware Meta-Disc version
1.4 (Universidad Complutense, Madrid, Spain).38
RESULTS
The search strategy identiﬁed 265 studies, 209 were
excluded, based on title and abstract, while the remain-
ing 56 were read and evaluated. Forty seven were further
excluded, based on prestated criteria leaving 9,
which were included in the ﬁnal meta-analysis29, 39–46
(Figure 1).
Studies identified in literature search
Studies read for evaluation
Studies included in meta-analysis
(n = 56)
(n = 265)
(n = 209)
(n = 9)
Excluded (n = 47)
Excluded (title and abstract
suggest study is not
appropriate)
Not able to extract 2x2 (n = 35)
Paediatric (n = 2)
Review (n = 5)
Non English (n = 3)
Other (n = 2)
 622 patients
Figure 1 | Flow diagram of studies identiﬁed in the systematic review.
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Data from 622 patients were available. Four of nine
studies were published in the early era (2002–2008) and
ﬁve were published in the late era (2009–2011). Five
studies were deemed to be of low quality (<12/23) and
the other four studies were deemed to be of high quality
( 12/23), according to the predescribed pro forma.32, 33
Four studies used PHES as their reference test, whereas
ﬁve studies used non-PHES as reference tests. Four stud-
ies were conducted in Europe, whereas ﬁve were per-
formed elsewhere. Six studies used a CFF cut-off value
of  38 Hz to distinguish an abnormal test, whereas the
other three used a cut-off value of  39 Hz. The median
(range) number of participants was 50 (31–114). Four
studies had less than 50 patients and ﬁve studies had 50
or more patients.
We grouped studies into MHE caused by cirrhosis
and MHE caused by bypass/shunting. Cirrhosis was the
cause of the MHE in seven studies, while bypass/shunt-
ing [secondary to extra-hepatic portal venous obstruction
(EHPVO)] was the cause in the other two.
Finally, we were unable to investigate different aetiolo-
gies of cirrhosis (such as alcohol or viral hepatitis) in
our meta-analysis, as it was not possible to extract sepa-
rate 2 9 2 tables for these aetiologies from the studies.
Sensitivity, speciﬁcity and diagnostic odds ratio
The pooled sensitivity for all nine studies included in the
ﬁnal meta-analysis was 61% (95% CI: 55–67%), pooled
speciﬁcity was 79% (95% CI: 75–83%), pooled positive LR
was 3.5 (95% CI: 2.0–6.1), pooled negative LR was 0.46
(95% CI: 0.31–0.68) and the pooled DOR was 10.9 (95%
CI: 4.2–28.3). (Table 1, Figure 2, Figures S1 and S2).
The Spearman correlation coefﬁcient for logit (TPR)
vs. logit (FPR) was 0.38 (P = 0.31), indicating a nonsig-
niﬁcant correlation between the TPR and FPR. The
Moses-Shapiro-Littenberg method showed that the DOR
was constant [b = 0.018 (P = 0.95)]. A symmetrical
sROC was therefore the most appropriate representation
of the diagnostic accuracy (Figure 3). It depicted an area
under the receiver operator curve (AUROC) (SE) of 0.84
(0.06) and with a Q statistic (SE) of 0.77 (0.06).
Heterogeneity analysis & subgroup analysis
Heterogeneity was detected in all pooled indices. For all
nine studies, the heterogeneity (I2) was 87% (sensitivity),
85% (speciﬁcity), 72% (positive LR), 85% (negative LR),
74% (DOR).
Subgroup analysis was performed to assess differences
in heterogeneity and diagnostic accuracy between the
prespeciﬁed groups (Table 2). The heterogeneity of the
DOR was lower in the high-quality studies (I2, 0% vs.
85%). There was less heterogeneity in studies, which
used a non-PHES gold standard test (I2, 5% vs. 88%).
We also found that there was less heterogeneity in the
European studies, compared with non-European studies
(I2, 45% vs. 72%). There was lower heterogeneity in the
smaller studies (I2, 17% vs. 77%), in the studies with a
CFF cut-off  39 (I2, 15% vs. 82%) and in the studies
published in the early era (I2, 40% vs. 78%).
Critical Flicker Frequency was more diagnostically
accurate in the European studies, DOR = 27.3 (95% CI:
8.2–91.2) compared with a DOR = 5.1 (95% CI: 1.6–
15.9) for non-European studies. CFF was also more
accurate in diagnosing MHE in studies performed in the
early era DOR = 26.6 (95% CI: 7.3–97.4) compared with
the late era DOR = 5.9 (95% CI: 1.8–19.4). Smaller stud-
ies (<50 patients) had a greater DOR = 32.5 (95% CI:
9.3–113.3), compared with the bigger studies ( 50
patients) DOR = 6.0 (95% CI: 2.1–17.2). There was little
difference in the DOR among the Quality (low/high),
cut-off ( 38/ 39) aetiology (bypass/cirrhosis) and the
gold standard (non-PHES/PHES) subgroups. To assess if
there was any signiﬁcant correlation between any of
these co-variables and the diagnostic accuracy of CFF
(DOR), meta-regression analysis was performed.
Meta-regression & Publication bias
There was no signiﬁcant correlation between any of the
covariates and the DOR in the univariate meta-regres-
sion analysis (Table 3). Owing to only nine studies being
included in this meta-analysis, the power of multivariate
meta-regression is low and thus this limits the overall
value of meta-regression in this meta-analysis.
No signiﬁcant publication bias was found in our study
sample, as the linear regression analysis indicates
P = 0.11 (Figure 4).
DISCUSSION
The importance of MHE as a complication of cirrhosis
or portosystemic bypass has only been recognised in the
last decade and its profound effect on patients with cir-
rhosis should not be underestimated. Neither, unfortu-
nately, should clinicians’ poor understanding of MHE
and hence their reluctance to test for its presence.18
Added to this, there are a number of diagnostic options,
but many clinicians are confused as to which to choose.
In the absence of other easily implementable clinical
alternatives, the PHES battery has been suggested as the
current gold standard internationally for MHE diagno-
sis,19 but patient numeracy, literacy or language skills
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may affect the result.47 CFF has been proposed as being
unaffected by these issues, but its diagnostic accuracy
has never been analysed quantitatively before.
There are a number of broad themes that emerged
from the meta-analysis. CFF only had a moderate pooled
sensitivity of 61% (95% CI: 55–67), but a good speciﬁcity
of 79% (95% CI: 75–83). The symmetrical sROC curve
had an AUROC of 0.84, indicating that CFF was effec-
tive in discriminating patients with MHE from those
without MHE and therefore has potential as a screening
tool, either to be used prior to current psychometrics
tools, or to be used alongside these tests, but not as a
replacement for them given the risk of false negative
results.
We used subgroup analysis to compare CFF diagnostic
accuracy in MHE caused by portosystemic bypass/shunt-
ing (DOR = 13.9), compared with MHE caused by cir-
rhosis (DOR = 10.6). Further analysis shows that CFF
has high speciﬁcity of 97% (95% CI: 87–100) for MHE in
patients with bypass/shunting (secondary to EHPVO),
0 0.2 0.4 0.6 0.8 1
Kircheis 2002
Romero-Gomez 2007
Montoliu 2007
Montoliu 2009
Dhiman 2010
Goel 2010
Sharma 2008
Sharma 2010
Maldonado-Garza 2011
Sensitivity
Pooled sensitivity 61 (55-67)%
I2 – 87%
0 0.2 0.4 0.6 0.8 1
Specificity
Pooled specificity 79 (75-83)%
I2 – 85%
Figure 2 | Forest plots for sensitivity and speciﬁcity for all nine studies.
Sensitivity
1-Specificity
SROC curve
Symmetric ROC
AUC – 0.84
SE (AUC) – 0.06
Q statistic – 0.77
SE (Q) – 0.06
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0 0.2 0.4 0.6 0.8 1
Figure 3 | Symmetrical Summary Receiver Operator Curve (sROC) for all nine studies.
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but a low sensitivity of 39% (95% CI: 20–59). Further
studies are needed to inform on whether CFF is effective
for diagnosing MHE caused by bypass/shunting, and
whether the pathogenesis of MHE in this condition pre-
determines the best diagnostic modality to choose. It may
be that the neurophysiological impairment of the
high ammonia states in portosystemic bypass/shunting
compared the potentially lower levels of hyperammona-
emia, but higher rates of inﬂammation in patients with
cirrhosis affect the performance of CFF in these
groups.48, 49
We found that the studies published in the early era
had a higher DOR than studies published in the late era
(DOR: 26.6 vs. 5.9). Although this difference was not sig-
niﬁcant on univariate meta-regression, it does question
whether the high DOR seen in early studies29 might rep-
resent an overestimation of diagnostic accuracy, particu-
larly when the test is applied to heterogeneous patient
cohorts. We also found that the diagnostic accuracy was
Table 2 | Assessment of diagnostic accuracy and heterogeneity in subgroup analysis
Sub groups
No. of
studies
Pooled
sensitivity
(95% CI)/%
Pooled
speciﬁcity
(95% CI)/%
Pooled
positive LR
(95% CI)
Pooled
negative LR
(95% CI)
Pooled
DOR (95% CI)
I2 (%)
DOR
All studies 9 61 (55–67) 79 (75–83) 3.5 (2.0–6.1) 0.46 (0.31–0.68) 10.9 (4.2–28.3) 74
Era
Early (2002–2008) 4 70 (59–80) 85 (78–90) 8.8 (2.0–38.2) 0.37 (0.26–0.54) 26.6(7.3–97.4) 40
Late (2009–2011) 5 57 (49–64) 75 (69–81) 2.6 (1.4–4.9) 0.58 (0.37–0.91) 5.9 (1.8–19.4) 78
Quality assessment
Low 5 54 (44–65) 81 (74–87) 5.0 (1.3–18.8) 0.47 (0.25–0.91) 14.1 (1.7–117.4) 85
High 4 65 (57–72) 78(71–83) 2.9(1.7–4.9) 0.42(0.24–0.73) 8.7(5.0–15.1) 0
Gold standard
Non-PHES 5 58(50–66) 84(78–90) 4.9(1.7–14.3) 0.53(0.35–0.79) 8.8 (4.4–17.6) 5
PHES 4 67 (57–76) 75 (68–81) 3.3 (1.4–8.0) 0.31 (0.10–1.00) 11.7 (1.8–74.5) 88
Location
Non-Europe 5 54 (46–62) 76 (70–82) 2.4 (1.2–4.6) 0.63 (0.44–0.91) 5.1 (1.6–15.9) 72
Europe 4 75 (65–83) 83 (76–89) 6.3 (2.3–17.2) 0.29 (0.16–0.51) 27.3 (8.2–91.2) 45
No. of patients
<50 4 65 (51–77) 93 (86–97) 8.1 (3.8–17.1) 0.32 (0.10–1.08) 32.5 (9.3–113.3) 17
 50 5 60 (53–67) 75 (69–80) 2.4 (1.4–4.0) 0.51 (0.32–0.80) 6.0 (2.1–17.2) 77
Cut-off
 38 6 57 (49–64) 80 (75–85) 4.0 (1.9–8.5) 0.44 (0.25–0.75) 12.0 (3.1–45.6) 82
 39 3 69(59–78) 76(66–84) 4.1(0.8–20.6) 0.48(0.21–1.06) 9.1 (3.2–25.6) 15
Aetiology of MHE
Bypass 2 39 (20–59) 97(87–100) 8.2 (1.1–59.8) 0.63 (0.29–1.37) 13.9 (1.0–186.4) 46
Cirrhosis 7 64 (57–70) 77 (72–81) 3.2 (1.9–5.6) 0.40 (0.25–0.67) 10.6 (3.7–30.5) 79
Study
Regression line
2.0
1.5
1.0
0.5
0.0
0.0 0.1 0.2 0.3 0.4
LO
G
 D
O
R
1/√ (ESS)
Figure 4 | Deeks’ funnel plot.
Table 3 | Results of univariate meta-regression
analysis of diagnostic odds ratio
Co-variables P-value RDOR 95% CI
Era (2002–2008)/(2009–2011) 0.15 0.19 (0.02–2.23)
Quality (low/high) 0.92 0.88 (0.05–15.11)
Gold Standard (non-PHES/PHES) 0.94 0.91 (0.04–21.29)
Location (non-Europe/Europe) 0.09 6.65 (0.70–63.62)
Number of patients (<50/ 50) 0.11 0.17 (0.02–1.77)
Cut-off ( 38/ 39) 0.95 0.92 (0.04–19.06)
Aetiology (Bypass/Cirrhosis) 0.90 0.77 (0.01–81.55)
RDORm, relative DOR.
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higher in studies published in Europe (DOR: 27.3 vs
5.1). Again, this showed no signiﬁcance on meta-regres-
sion analysis, but may represent an early indicator that
CFF may be more accurate in European patients. It
remains unclear why this objective, language-indepen-
dent test would perform better in these subgroups, but it
is an important observation and does have implications
on the role of CFF as a worldwide screening tool for
MHE, particularly when the sensitivity is only 54% in
the non-European, compared with 75% in the European
subgroups.
We explored the possibility that early studies outper-
formed later studies due to the problem of publication
bias, and we acknowledge that it can be a signiﬁcant
problem with diagnostic accuracy meta-analysis, but we
found no statistical evidence of this across our study
sample. We are also aware that four of the ﬁve non-
European studies were published in India41, 43–45 and
two of them by the same centre. Further studies are
regarding the effect of location and race on this diagnos-
tic test, particularly in non-European countries outside
of India.
The considerable amount of heterogeneity detected
between the studies suggests a need for caution when
pooling the diagnostic accuracy measures together. We
used subgroup analysis to assess the heterogeneity in
prespeciﬁed groups, and unsurprisingly found that it was
reduced in the ‘high quality’ studies. The implicit and
explicit causes of threshold effect were assessed as
another cause of heterogeneity. Most studies used either
38 Hz or 39 Hz as the ﬂicker frequency cut-off value to
discriminate between patients with or without MHE;
when this was assessed in the meta-regression analysis,
there was no correlation between this value and the
DOR. We further assessed the implicit causes of thresh-
old effect by calculating the Spearman correlation, which
was 0.38 (P = 0.31). While there was no statistical evi-
dence of a threshold effect, a summary ROC (sROC)
remains a useful composite measure of the diagnostic
accuracy of CFF.50 The Moses model showed the DOR
to be constant, so we investigated further using a sym-
metrical sROC conﬁrming the good overall accuracy of
CFF.35
One limitation of this meta-analysis is that the nine
studies included had to compare CFF to a reference test.
This provides two problems: ﬁrst, the reference test is
not the same for all nine studies; and second, the diag-
nostic accuracy of this test may be less than 100%.
Within the subgroup analysis, we looked at studies that
compared CFF with PHES (the current suggested diag-
nostic gold standard) and studies that referenced to
another non-PHES test (Table 1). Attempts were made
to assess differences in heterogeneity and diagnostic
accuracy between these two groups. The diagnostic accu-
racy for CFF was slightly higher in the PHES subgroup
(DOR: 11.7 vs. 8.8), but also signiﬁcantly more heteroge-
neous (DOR: 88% vs. 5%). Although there is some dif-
ference in diagnostic accuracy, the meta-regression
analysis showed no signiﬁcance. We can, therefore, cau-
tiously conclude from this meta-analysis that CFF seems
to perform comparably to PHES and non-PHES diag-
nosed MHE. The increase in heterogeneity observed may
thus be explained to some extent.
One further limitation common to all diagnostic
meta-analyses is the lack of clarity, quality and stan-
dardisation in diagnostic studies’ methodology. Studies
were assessed for quality using STARD pro forma to
quantify the methodology of the study design. We had
to exclude two studies at a late stage due to ambiguity
between the raw data and the diagnostic accuracy data,
which could not be resolved with the authors.51, 52
Furthermore, it should be noted that Maldonado-Garza
and colleagues’ study, for example, was not intended to
be a diagnostic study, yet included sufﬁcient data to
enable its inclusion in this meta-analysis. We would
encourage any further studies designed to assess the
diagnostic accuracy of CFF to follow either the STARD
or PRISMA checklist.
Despite the limitations, we know that CFF is a simple,
affordable test, which is easy to perform. It is thus realis-
tic for departments specialising in the management of
patients with cirrhosis or portosystemic bypass/shunting,
who are at high risk of MHE, to buy and use this device.
The test does not require specialist personnel to conduct
and is extremely well tolerated and easily understood by
the patients within the studies. The only limitation of its
use in the nine studies was in Romero-Gomez and col-
leagues study where nine patients and three controls
could not perform the test due to visual impairment or
inability to understand the fundamentals involved.39
Key to the management algorithm of MHE is a cor-
rect, early diagnosis, prompting early effective treat-
ment.13–17 Many of the diagnostic tests available at
present are time consuming and require trained person-
nel to perform them. Furthermore, the lack of universal
consensus on which diagnostic methods and strategies
should be implemented heightens the problem of under-
diagnosis and as demonstrated, no uniformly imple-
mented international gold standard diagnostic testing
criteria for MHE exist. This meta-analysis has shown
534 Aliment Pharmacol Ther 2013; 37: 527-536
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that CFF is a diagnostically accurate test, which could be
used as an adjunct to conventional psychometric test
batteries, such as PHES, but could only become a
replacement screening test if further studies show an
improvement in sensitivity.
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